RLAY Relay Therapeutics, Inc.

8-K Current Report

Filed: March 16, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc. (RLAY) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Phase 1/2 ReDiscover trial data released for zovegalisib (RLY-2608) + fulvestrant combo in PI3Kα-mutated HR+/HER2- metastatic breast cancer
• Recommended Phase 3 dose confirmed at 400mg BID with food — key de-risking milestone ahead of potential pivotal trial

+2 more insights

Item 8.01 · Other Events

• Median PFS 11.1 months at 400mg BID fed dose in 57 efficacy-evaluable PI3Kα-mutated HR+/HER2- metastatic breast cancer patients
• Confirmed ORR 43% overall; 52% in second-line-only patients — clinically meaningful response rates supporting Phase 3 advancement

+3 more insights

Other Relay Therapeutics, Inc. 8-K Filings

8-K Mar 11, 2026

8-K Feb 26, 2026

Get deeper insights on Relay Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.